Form 8-K Karyopharm Therapeutics For: Aug 07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Karyopharm Therap (KPTI) Misses Q2 EPS by 52c
August 7, 2014 8:38 AM EDTKaryopharm Therap (NASDAQ: KPTI) reported Q2 EPS of ($1.02), $0.52 worse than the analyst estimate of ($0.50). Revenue for the quarter came in at $21 thousand versus the consensus estimate of $150 thousand.
For earnings history and earnings-related data on Karyopharm Therap (KPTI) click here.
... More